Психиатрия Психиатрия и психофармакотерапия им. П.Б. Ганнушкина
№03 2021

Список исп. литературыСкрыть список

1. Sadock B.J., Sadock V.A., Ruiz P., Kaplan H.I. Kaplan & Sadock's Comprehensive
Textbook of Psychiatry. 9th. / Philadelphia, Pa, USA: Wolters Kluwer
Health/Lippincott Williams & Wilkins. 2009. 4520 p.
2. American Psychiatric Association. Diagnositc and Statistical Manual of
Mental Disorders / Arlington, Va, USA: American Psychiatric Association.
2013.
3. Khademvatan S., Saki J., Khajeddin N. et al. Toxoplasma gondii exposure
and the risk of schizophrenia // Jundishapur Journal of Microbiology. 2014.
Vol. 7, N.11:e12776.
4. Khademvatan S., Khajeddin N., Izadi S., Yousefi E. Investigation of anti-
Toxocara and anti-Toxoplasma antibodies in patients with schizophrenia
disorder // Schizophrenia Research and Treatment. 2014. Vol. 2014. 7 p.
5. Lau C.I., Wang H.C., Hsu J.L., Liu M.E. Does the dopamine hypothesis explain
schizophrenia? // Rev. Neurosci. 2013. Vol. 24. P.389–400.
6. Hu W., MacDonald M.L., Elswick D.E., Sweet R.A. The glutamate hypothesis
of schizophrenia: Evidence from human brain tissue studies // Ann.
N.Y. Acad. Sci. 2015. Vol.1338. P.38–57.
7. Akhondzadeh S., Rezaei F., Larijani B. et al. Correlation between testosterone,
gonadotropins and prolactin and severity of negative symptoms in
male patients with chronic schizophrenia // Schizophrenia Research. 2006.
Vol. 84. Suppl. 2-3. P.405–410.
8. Ko Y.H., Jung S.W., Joe S.H. et al. Association between serum testosterone
levels and the severity of negative symptoms in male patients with chronic
schizophrenia // Psychoneuroendocrinology. 2007. Vol. 32. N. 4. P. 385–
391.
9. Shirayama Y., Hashimoto K., Suzuki Y., Higuchi T. Correlation of plasma
neurosteroid levels to the severity of negative symptoms in male patients
with schizophrenia // Schizophrenia Research. 2002. Vol. 58. N. 1. P.
69–74.
10.Weiden P.J., Miller A.L. Which side effects really matter? Screening for common
and distressing side effects of antipsychotic medications // J Psychiatr
Pract. 2001. Vol. 7. P. 41–47.
11. Abraham G., Paing W.W., Kaminski J. et al. Effects of elevated serum prolactin
on bone mineral density and bone metabolism in female patients with
schizophrenia: a prospective study // Am J Psychiatry. 2003. Vol. 160. P.
1618–1620.
12. Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels
in patients with schizophrenia: mechanisms and related adverse effects //
Psychoneuroendocrinology. 2003. Vol. 28. N. 1. P.53–67.
13. Kishimoto T., Watanabe K., Shimada N. et al. Antipsychotic-induced hyperprolactinemia
inhibits the hypothalamo-pituitary-gonadal axis and reduces
bone mineral density in male patients with schizophrenia // J Clin
Psychiatry. 2008. Vol. 69. P. 385–391.
14.Wieck A., Haddad P.M. Antipsychotic-induced hyperprolactinaemia in
women: pathophysiology, severity and consequences: selective literature review
// The British Journal of Psychiatry. 2003. Vol. 182. N. 3. P. 199–204.
15. Montejo A.L., Arango C., Bernardo M. et al. Spanish consensus on the risks
and detection of antipsychotic drug-related hyperprolactinaemia // Revista de
Psiquiatría y Salud Mental (English Edition). 2016. Vol. 9. N. 3. P. 158–173.
16. Montejo Á.L., Arango C., Bernardo M. et al. Multidisciplinary consensus
on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary
to antipsychotics // Frontiers in Neuroendocrinology. 2017. Vol.
45. P. 25–34.
17. Vitiello B., Correll C., van Zwieten-Boot B. et al. Antipsychotics in children
and adolescents: increasing use, evidence for efficacy and safety concerns //
European Neuropsychopharmacology. 2009. Vol. 19. N. 9. P. 629–635.
18. Cookson J., Hodgson R., Wildgust H.J. Prolactin, hyperprolactinaemia and
antipsychotic treatment: a review and lessons for treatment of early psychosis
// Journal of Psychopharmacology. 2012. Vol. 26. N. 5. P. 42–51.
19. Bahar A., Akha O., Kashi Z., Vesgari Z. Hyperprolactinemia in association
with subclinical hypothyroidism // Caspian journal of internal medicine.
2011. Vol. 2. N. 2. P. 229.
20. La Torre D., Falorni A. Pharmacological causes of hyperprolactinemia //
Therapeutics and Clinical Risk Management. 2007. Vol.3. N. 5. P.929.
21. Kim S., Park Y.M. Serum prolactin and macroprolactin levels among outpatients
with major depressive disorder following the administration of selective
serotonin-reuptake inhibitors: a cross-sectional pilot study // PLoS One.
2013. Vol.8. N. 12:e82749.
22. Meltzer H.Y., Sachar E.J., Frantz A.G. Serum prolactin levels in unmedicated
schizophrenic patients // Archives of General Psychiatry. 1974. Vol.31. N.
4. P. 564–569.
23. Muneyyirci-Delale O., Goldstein D., Reyes F.I. Diagnosis of stress-related
hyperprolactinemia. Evaluation of the hyperprolactinemia rest test // New
York state journal of medicine. 1989. Vol. 89. N. 4. P. 205–208.
24. Sonino N., Navarrini C., Ruini C. et al. Life events in the pathogenesis of
hyperprolactinemia // European journal of endocrinology. 2004. Vol. 151.
N. 1. P. 61–65.
25. Segal M., Avital A., Rojas M. et al. Serum prolactin levels in unmedicated
first-episode and recurrent schizophrenia patients: a possible marker for the
disease's subtypes // Psychiatry research. 2004. Vol. 127. N. 3. P. 227–235.
26. Garver D.L., Holcomb J.A., Christensen J.D. Heterogeneity of response to
antipsychotics from multiple disorders in the schizophrenia spectrum // The
Journal of clinical psychiatry. 2000. Vol. 61. N. 12. P. 964–972.
27. Meaney A.M., O’Keane V. Prolactin and schizophrenia: clinical consequences
of hyperprolactinaemia // Life Sci. 2002. Vol.71. N. 9. P. 979–992.
28. Hamner M.B., Arana G.W. Hyperprolactinaemia in antipsychotictreated
patients. Guidelines for avoidance and management // CNS Drugs. 1998.
Vol. 10. N. 3. P. 209–222.
29. Zhang-Wong J.H., Seeman M.V. Antipsychotic drugs, menstrual regularity
and osteoporosis risk // Arch Womens Ment Health. 2002. Vol. 5. N. 3. P.
93–98.
30. Citrome L. Current guidelines and their recommendations for prolactin monitoring
in psychosis // J Psychopharmacol. 2008. Vol. 22. N. 2. P. 90–97.
31. Peuskens J. A literature review of «Prolactin in schizophrenia» // Clear perspectives:
management issues in schizophrenia. 1997. Vol. 1, Issue 3. 42 p.
32. Rivera L., Lal S., Ettigi P. et al. Effect of acute and chronic neuroleptic therapy
on serum prolactin levels in men and women of different age groups
// Clinical endocrinology. 1976. Vol. 5. N. 3. P. 273-282.
33. Naber D., C., Fischer B. et al. Effect of long-term neuroleptic treatment on
prolactin and norepinephrine levels in serum of chronic schizophrenics: relations
to psychopathology and extrapyramidal symptoms // Neuropsychobiology.
1980. Vol. 6. N. 4. P. 181-189.
34. Rao M.L., Brown W.A. Stability of serum neuroleptic and prolactin concentrations
during short- and long-term treatment of schizophrenic patients
// Psychopharmacology (Berl). 1987. Vol. 93. N. 2. P. 237-242.
35. Qijing Bo, Fang Dong, Xianbin Li et al. Prolactin related symptoms during
risperidone maintenance treatment: results from a prospective, multicenter
study of schizophrenia. // BMC Psychiatry. 2016. Vol. 16. P. 386.
36. Peuskens J., Pani L., Detraux J., De Hert M. The effects of novel and newly
approved antipsychotics on serum prolactin levels: a comprehensive review
// CNS Drugs. 2014. Vol. 28. N. 5. P. 421–453.
37. Einarson T.R, Hemels M.E., Nuamah I. et al. An analysis of potentially prolactin-
related adverse events and abnormal prolactin values in randomized
clinical trials with paliperidone palmitate // Ann Pharmacother. 2012. Vol.
46. N. 10. P.1322–1330.
38. Kleinberg D.L., Davis J.M., de Coster R. et al. Prolactin levels and adverse
events in patients treated with risperidone // J Clin Psychopharmacol. 1999.
Vol. 19. N. 1. P. 57–61.
39. Eberhard J., Lindstrom E., Holstad M. et al. Prolactin level during years of
risperidone treatment in patients with psychotic disorders // Acta Psychiatr
Scand. 2007. Vol. 115. N. 4. P. 268–276.
40. Marken P.A., Haykal R.F., Fisher J.N. Management of psychotropic-induced
hyperprolactinemia // Clin Pharm. 1992. Vol. 11. N. 10. P. 851–856.
41. Brown W.A., Laughren T.P. Tolerance to the prolactin-elevating effect of
neuroleptics. // Psychiatry Res. 1981. Vol. 5. N. 3. P. 317–322.
42. Meltzer H.Y., Fang V.S. The effect of neuroleptics on serum prolactin in
schizophrenic patients // Arch Gen Psychiatry.1976. Vol. 33. N. 3. P. 279–
286.
43. Meltzer H.Y., Fang V.S. Serum prolactin levels in schizophrenia – effect of
antipsychotic drugs: a preliminary report / In: Sachar EJ, editor. Hormones,
behaviour, and psychopathology. New York: Raven Press; 1976. P. 177–190.
44. Igarashi Y., Higuchi T., Toyoshima R. et al. Tolerance to prolactin secretion
in the long-term treatment with neuroleptics in schizophrenia // Adv Biochem
Psychopharmacol. 1985. Vol. 40. P. 95–98.
45. Meltzer H.Y. Long-term effects of neuroleptic drugs on the neuroendocrine
system // Adv Biochem Psychopharmacol. 1985. Vol. 40. P. 59–68.
46. Ahn Y.M., Lee K.Y, Kim C.E. et al. The acute and long-term effectiveness
of amisulpride in patients with schizophrenia: of a 12-month open-label
prospective follow-up study // Hum Psychopharmacol. 2011. Vol. 26. N. 8.
P. 568–577.
47. Kim E.Y., Kim S.H., Lee N.Y. et al. Relationship between prolactin levels
and subjective endocrine-related adverse effects in patients with schizophrenia
receiving long-term treatment with amisulpride // Pharmacopsychiatry.
2012. Vol. 45. N. 2. P. 57–63.
48. Dehelean L., Romosan A.M, Papava I. et al. Prolactin response to antipsychotics:
An inpatient study // PLoS ONE. 2020. Vol. 15. N. 2: e0228648.
49. Kapur S., Zipursky R., Jones C. et al. Relationship between dopamine D2
occupancy, clinical response, and side effects: a double-blind PET study of
first-episode schizophrenia // American Journal of Psychiatry. 2000. Vol.
157. N. 4. P. 514–520.
50. Gruen P.H., Sachar E.J., Langer G. et al. Prolactin responses to neuroleptics
in normal and schizophrenic subjects // Archives of General Psychiatry.
1978. Vol. 35. N. 1. P. 108–116.
51. Gruen P.H., Sachar E.J., Altman N. et al. Relation of plasma prolactin to clinical
response in schizophrenic patients // Archives of general psychiatry.
1978. Vol. 35, N. 10. P. 1222–1227.
52. Zhang X.Y., Zhou D.F., Yuan C.L. et al. Risperidone-induced increase in
serum prolactin is correlated with positive symptom improvement in chronic
schizophrenia // Psychiatry research. 2002. Vol. 109. N. 3. P. 297–302.
53. Faraone S.V., Brown W.A, Laughren T.P. Serum neuroleptic levels, prolactin
levels, and relapse: a twoyear study of schizophrenic outpatients // The
Journal of clinical psychiatry. 1987. Vol. 48. P. 151–154.
54. Brown W.A. Neuroleptics and Prolactin / In Psychoneuroendocrine Dysfunction.
Springer, Boston, MA. 1984. P. 569–582.
55. Tandon R., Mazzara C., DeQuardo J. et al. Dexamethasone suppression test
in schizophrenia: relationship to symptomatology, ventricular enlargement,
and outcome. // Biological Psychiatry. 1991. Vol. 29. N. 10. P. 953–964.
56. Pariante C.M., Vassilopoulou K., Velakoulis D. et al. Pituitary volume in
psychosis. The // British Journal of Psychiatry. 2004. Vol. 185. N. 1. P. 5–
10.
57. Lum C., Kucharczyk W., Montanera W.J., Becker L.E. The sella turcica and
parasellar region / Magnetic Resonance Imaging of the Brain and Spine.
Lippincott, Williams and Wilkins: Philadelphia. 2002. P. 1283–1362.
58. Karoum F., Karson C.N., Bigelow L.B. et al. Preliminary evidence of reduced
combined output of dopamine and its metabolites in chronic schizophrenia
// Archives of General Psychiatry. 1987. Vol. 44. N. 7. P. 604–607.
59. Lieberman J.A., Alvir J.M., Koreen A. et al. Psychobiologic correlates of treatment
response in schizophrenia // Neuropsychopharmacology. 1996. Vol.
14. N. 3. P. 13–21.
60. Naber D., Mueller F. Effects of Long-Term Neuroleptic Treatment on
Serum Levels of Prolactin, TSH, LH, and Norepinephrine and on α-Adrenergic
and Dopaminergic Receptor Sensitivity / In Psychoneuroendocrine
Dysfunction. Springer, Boston, MA. 1984. P. 599–612.
61. Hayes E., Gavrilidis E., Kulkarni J. The role of oestrogen and other hormones
in the pathophysiology and treatment of schizophrenia // Schizophrenia
Research and Treatment. 2012. Vol. 2012. 8 p.